Kibow Pharma
6
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study
Role: lead
Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV
Role: lead
Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure
Role: lead
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis
Role: lead
Observational Study of Kibow Biotics in Dialysis Patients
Role: lead
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients
Role: lead
All 6 trials loaded